Condition
Diphtheria, Tetanus and Acellular Pertussis
Total Trials
3
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
Treatment Research
15 treatments under study, led by Diphtheria Tetanus And Acellular Pertussis Three Components Combined Vaccine Adsorbed Dtcp
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Phase 1 (1)
Phase 3 (2)
Trial Status
Active Not Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07203755Phase 1RecruitingPrimary
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
NCT06857370Phase 3Active Not RecruitingPrimary
Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine
NCT05951725Phase 3Active Not RecruitingPrimary
A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)
Showing all 3 trials
Research Network
Common Treatments
- Diphtheria Tetanus And Acellular Pertussis Three Components Combined Vaccine Adsorbed Dtcp1
- Diphtheria Tetanus And Acellular Pertussis Three Components Combined Vaccine Adsorbed Dtcp Lot 21
- Diphtheria Tetanus And Acellular Pertussis Three Components Combined Vaccine Adsorbed Dtcp Lot 11
- Diphtheriatetanuspertussisacellularcomponentinactivated Polio Vaccineadsorbedand Haemophilus Influenzae Type B Conjugate Vaccineadsorbeddtapipvhib1
- Dtcphibmcv41
Active Sponsors
- CanSino Biologics Inc.3
Top Investigators
Henan Center for Disease Control and Prevention
Related Conditions
- Epidemic Meningitis1
- Haemophilus Influenzae Type B Infection1